Bactericidal/permeability-increasing protein (BPI) - 1.0mg

Bactericidal/permeability-increasing protein (BPI) - 1.0mg

Regular price
$3,920.52
Regular price
Sale price
$3,920.52
Unit price
per 
Availability
Sold out

Bactericidal/permeability-increasing protein


CAP57 
Uniprot ID:  P17213
mRNA RefSeq:  NM_001725
Protein RefSeq:  NP_001716
Size: 1.0mg
Source: Human Neutrophils


Product Information

The existence of autoantibodies to bactericidal/permeability-increasing protein (BPI) was first described when it was noticed that 11 of 51 sera that were cANCA positive in immunofluorescence, recognized a 57 kDa antimicrobial cationic protein known as CAP57 in both ELISA and Western blot.  It is now known that CAP57 and BPI are identical.

More recently BPI purified from neutrophil granula was used to directly demonstrate the existence of anti-BPI autoantibodies in a range of vasculitic disorders by ELISA and Western blot. BPI-ANCA have since been demonstrated to be present in a range of clinical conditions including ulcerative colitis, Crohn’s disease, cystic fibrosis, rheumatoid arthritis, systemic lupus erythematosus, mixed connective tissue disease, Behcet’s disease, bronchieactasis, primary sclerosing cholangitis and chronic liver diseases.

BPI is a highly cationic protein that is stored in the azurophil granula of neutrophils. BPI is a potent antibacterial agent with selective toxicity towards Gram-negative bacteria. It binds to the lipopolysaccharides present in the outer envelope of these bacteria to exert immediate bacteriostatic effects and later, bactericidal effects. Analysis of the activity of proteolytic fragments and of the crystal structure of BPI reveal that the protein consists of two functionally distinct domains: a potent antibacterial and anti-endotoxin 20 kDa domain at the amino-terminal and a carboxyl terminal domain that is responsible for BPI’s opsonic activity.

Epitope studies using a panel of recombinant truncated BPI proteins indicate that anti-neutrophil cytoplasmic antibodies to BPI recognise the carboxyl terminal domain. It has also been suggested elsewhere that BPI-ANCA binding sites are likely to be conformational epitopes, as is the case with autoantibodies to proteinase 3 and myeloperoxidase. 

PDF-logo-dl BPI datasheet


Clinical Indications:

Primary Sclerosing Cholangitis
Crohn's disease
Ulcerative Colitis
Glomerular diseases

MSDS:


References:

Falk, R.J. et al. (1991) Am. J. Kidney Dis. 18, 197 (abstract 6)

Pereira, H.A. et al. (1990) Blood 76, 825

Zhao, M.H. et al. (1995) Clin. Exp. Immunol. 99, 49

Cooper, T. et al. (2000) Rheumatol. Int. 19, 129Aebi, C. et al. (2000) Pediatr. Infect. Dis. J. 19, 207

Burrows, N.P. et al. (1996) J. R. Soc. Med. 89, 47

PFolwaczny C. et al. (1998) Z. Gastroenterol 36, 625

Lindgren, S. et al. (2000) J. Gastroenterol. Hepatol. 15, 437

Locht, H. et al. (2000) Ann. Rheum. Dis. 59, 898

Mahadeva, R. et al. (1999) Clin. Exp. Immunol. 117, 561

Manolova, I. (2001) Rheumatol. Int. 20, 197

Matsuyama, W. et al. (1999) Intern. Med. 38, 813

Roozendaal, C. et al. (1998) Am. J. Med. 105, 393

Schnabel, A. et al. (1997) Med. Klin. 92, 389

Schultz, H. et al. (2000) Pediatr. Allergy Immunol. 11, 64

Sediva, A. et al. (1998) J. Autoimmun. 11, 185

Stoffel, M.P. et al. (1996) Clin. Exp. Immunol. 104, 54

Vecchi, M. et al. (1998) Scan. J. Gastroenterol. 33, 1284

Walmsley, R.S. et al. (1997) Gut 40, 105

Zhao, M.H. et al. QJM (1996) 89, 259

Weiss, J. et al. (1978) J. Biol. Chem. 253, 2664

Weiss, J. & Olsson, I. (1987) Blood 69, 652

Elsbach, P. & Weiss, J. (1993) Immunobiology 187, 417

Mannion, B.A. et al. (1990) J. Clin. Invest. 85, 853

Capodici, C. & Weiss, J. (1996) J. Immunol. 156, 4789

Beamer, L.J. et al. (1997) Science 276, 1861

Dunn, A.C. et al. (1999) J. Infect. 39, 81

Schultz, H. et al. (2000) Pediatr. Allergy Immunol. 11, 64

Schultz, H. et al. (1997) J. Immunol. Methods 205, 127

Schultz, H. et al. (2001) J. Leukocyte Biol. 69, 505